QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
| Revenue (Most Recent Fiscal Year) | $1.98B |
| Net Income (Most Recent Fiscal Year) | $83.59M |
| PE Ratio (Current Year Earnings Estimate) | 19.85 |
| PE Ratio (Trailing 12 Months) | 19.75 |
| PEG Ratio (Long Term Growth Estimate) | 2.39 |
| Price to Sales Ratio (Trailing 12 Months) | 5.03 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.85 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 14.61 |
| Pre-Tax Margin (Trailing 12 Months) | 24.48% |
| Net Margin (Trailing 12 Months) | 19.58% |
| Return on Equity (Trailing 12 Months) | 14.80% |
| Return on Assets (Trailing 12 Months) | 8.86% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.60 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.30 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.45 |
| Inventory Turnover (Trailing 12 Months) | 2.67 |
| Book Value per Share (Most Recent Fiscal Quarter) | $16.05 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.61 |
| Earnings per Share (Most Recent Fiscal Year) | $2.18 |
| Diluted Earnings per Share (Trailing 12 Months) | $1.84 |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 222.29M |
| Free Float | 202.28M |
| Market Capitalization | $10.41B |
| Average Volume (Last 20 Days) | 1.09M |
| Beta (Past 60 Months) | 0.68 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 9.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 70.00% |
| Annual Dividend (Based on Last Quarter) | $0.25 |
| Dividend Yield (Based on Last Quarter) | 0.53% |